

115TH CONGRESS  
1ST SESSION

# H. R. 4724

To provide for a demonstration project to further examine the benefits of providing coverage and payment for items and services necessary to administer intravenous immune globulin (IVIG) in the home, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

DECEMBER 21, 2017

Mr. HOLDING (for himself, Mr. BLUMENAUER, Mr. LANCE, Mr. BUTTERFIELD, and Mr. MEEHAN) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To provide for a demonstration project to further examine the benefits of providing coverage and payment for items and services necessary to administer intravenous immune globulin (IVIG) in the home, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Medicare IVIG Access  
5 Enhancement Act”.

1 **SEC. 2. MEDICARE PATIENT IVIG ACCESS DEMONSTRATION**  
2 **PROJECT.**

3 (a) ESTABLISHMENT.—The Secretary of Health and  
4 Human Services (in this section referred to as the “Sec-  
5 retary”) shall establish and implement a demonstration  
6 project under part B of title XVIII of the Social Security  
7 Act to evaluate the benefits of providing payment for items  
8 and services needed for the in-home administration of in-  
9 travenous immune globulin for the treatment of chronic  
10 inflammatory demyelinating polyneuropathy or multifocal  
11 motor neuropathy.

12 (b) DURATION AND SCOPE.—

13 (1) DURATION.—Beginning not later than 1  
14 year after the date of enactment of this Act, the  
15 Secretary shall conduct the demonstration project  
16 for a period of 3 years.

17 (2) SCOPE.—The Secretary shall enroll not  
18 greater than 3,000 Medicare beneficiaries who have  
19 been diagnosed with chronic inflammatory demyelin-  
20 ating polyneuropathy or multifocal motor neurop-  
21 athy for participation in the demonstration project.  
22 A Medicare beneficiary may participate in the dem-  
23 onstration project on a voluntary basis and may ter-  
24minate participation at any time.

25 (c) COVERAGE.—Except as otherwise provided in this  
26 section, items and services for which payment may be

1 made under the demonstration program shall be treated  
2 and covered under part B of title XVIII of the Social Se-  
3 curity Act in the same manner as similar items and serv-  
4 ices covered under such part.

5 (d) PAYMENT.—

6 (1) INTRAVENOUS IMMUNE GLOBULIN.—For in-  
7 travenous immune globulin furnished under this sec-  
8 tion, the Secretary shall make payment using the  
9 payment methodology under section 1847A of the  
10 Social Security Act (42 U.S.C. 1395w–3a).

11 (2) OTHER ITEMS AND SERVICES.—

12 (A) IN GENERAL.—The Secretary shall es-  
13 tablish, subject to subparagraph (B), a per-visit  
14 payment amount for items and services (other  
15 than intravenous immune globulin) needed for  
16 the in-home infusion of intravenous immune  
17 globulin for the treatment of chronic inflam-  
18 matory demyelinating polyneuropathy or multi-  
19 focal motor neuropathy based on the national  
20 per visit low-utilization payment amount under  
21 the prospective payment system for home health  
22 services established under section 1895 of the  
23 Social Security Act (42 U.S.C. 1395fff).

24 (B) LIMITATION.—The per-visit payment  
25 amount established under subparagraph (A) for

1 items and services described in such subpara-  
2 graph shall not be less than the payment  
3 amount applied under the demonstration  
4 project established under section 101 of the  
5 Medicare IVIG Access and Strengthening Medi-  
6 care and Repaying Taxpayers Act of 2012  
7 (Public Law 112–242) for comparable items  
8 and services needed for the in-home administra-  
9 tion of intravenous immune globulin for the  
10 treatment of primary immune deficiency dis-  
11 eases.

12 (e) WAIVER AUTHORITY.—The Secretary may waive  
13 such requirements of title XVIII of the Social Security Act  
14 as may be necessary to carry out the demonstration  
15 project.

16 (f) REPORTS TO CONGRESS.—

17 (1) INTERIM EVALUATION AND REPORT.—Not  
18 later than 3 years after the date of enactment of  
19 this Act, the Secretary shall submit to Congress a  
20 report that contains—

21 (A) an evaluation of the impact of the  
22 demonstration project on access for Medicare  
23 beneficiaries with chronic inflammatory demye-  
24 linating polyneuropathy and Medicare bene-  
25 ficiaries with multifocal motor neuropathy to

1 items and services needed for the in-home ad-  
2 ministration of intravenous immune globin; and

3 (B) an analysis of the appropriateness of  
4 expanding or extending the demonstration  
5 project or implementing a new methodology for  
6 payment for intravenous immune globulins in  
7 all care settings under part B of title XVIII of  
8 the Social Security Act (42 U.S.C. 1395k et  
9 seq.) and, to the extent such analysis deter-  
10 mines such an expansion, extension, or method-  
11 ology appropriate, recommendations for such  
12 expansion, extension, or methodology, respec-  
13 tively.

14 (2) FINAL EVALUATION AND REPORT.—Not  
15 later than one year after the date of completion of  
16 the demonstration project, the Secretary shall sub-  
17 mit to Congress a report that contains—

18 (A) a final evaluation of the impact de-  
19 scribed in paragraph (1)(A); and

20 (B) a final analysis and recommendations  
21 described in paragraph (1)(B).

22 (g) DEFINITIONS.—In this section:

23 (1) DEMONSTRATION PROJECT.—The term  
24 “demonstration project” means the demonstration  
25 project conducted under this Act.

1           (2)   MEDICARE   BENEFICIARY.—The   term  
2           “Medicare beneficiary” means an individual who is  
3           enrolled for benefits under part B of title XVIII of  
4           the Social Security Act.

○